[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ntrk1-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"NTRK1 Gene",5,[7,15,21,28,34],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04879121","Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors",[11],"Phase 2","RECRUITING","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.578999Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06528691","Entrectinib as a Single Agent in Upfront Therapy for Children \u003C3 Years of Age With NTRK1\u002F2\u002F3 or ROS1-FUSED CNS Tumors",[11],"2026-08-26T02:16:46.951087Z","2026-05-05T02:35:31.919545Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT05004116","A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer",[25],"Phase 1\u002FPhase 2","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.261412Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT03093116","A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",[25],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.489051Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT03556228","VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma",[25],"2026-08-26T02:16:45.157238Z","2026-05-05T02:35:31.649315Z"]